▶ 調査レポート

全身性炎症反応症候群治療の世界市場:市場規模、シェア、成長、動向、予測

• 英文タイトル:Systemic Inflammatory Response Syndrome Treatment Market (Indication: Meningitis, Urinary Tract Infection (UTI), Pneumonia, Hemorrhage, Autoimmune Diseases, Others; End User: Hospital & Ambulatory Surgical Centers, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。全身性炎症反応症候群治療の世界市場:市場規模、シェア、成長、動向、予測 / Systemic Inflammatory Response Syndrome Treatment Market (Indication: Meningitis, Urinary Tract Infection (UTI), Pneumonia, Hemorrhage, Autoimmune Diseases, Others; End User: Hospital & Ambulatory Surgical Centers, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-NV171資料のイメージです。• レポートコード:TPM-NV171
• 出版社/出版日:Transparency Market Research / 2019年10月28日
• レポート形態:英文、PDF、195ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥782,325 (USD5,795)▷ お問い合わせ
  Multi User¥1,187,325 (USD8,795)▷ お問い合わせ
  Global Site License¥1,592,325 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、全身性炎症反応症候群治療の世界市場について調べ、全身性炎症反応症候群治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、疾患別(髄膜炎、尿路感染症(UTI)、肺炎、出血、自己免疫疾患、その他)分析、エンドユーザー別(病院および外来手術センター、専門クリニック、その他)分析、関連企業情報などをまとめました。
・全身性炎症反応症候群治療の市場概要
・全身性炎症反応症候群治療の市場動向
・全身性炎症反応症候群治療の世界市場規模・予測
・全身性炎症反応症候群治療市場:疾患別(髄膜炎、尿路感染症(UTI)、肺炎、出血、自己免疫疾患、その他)
・全身性炎症反応症候群治療市場:エンドユーザー別(病院および外来手術センター、専門クリニック、その他)
・地域別分析(北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米)
・競争環境・関連企業分析

The systemic inflammatory response syndrome treatment market is anticipated to grow from ~US$ 9.8 Bn in 2019 to ~US$ 17.8 Bn by 2027, and this healthy growth is attributable to government initiatives taken towards reducing the mortality rate of patients diagnosed with sepsis. Advancements in SIRS therapeutics are further brought in due to investment firms established in developed countries, who fund numerous clinical development programs that possess the capability of formulating effective drugs.

According to the World Health Organization, 7/100 hospitalized patients are highly susceptible to infections, which can cause sepsis. The patient-susceptibility rate in developing countries exceeds even this seven-one-hundred ratio, which signifies profitable opportunities for the systemic inflammatory response syndrome treatment market, as consumers tend to gain financial lucidity along with health consciousness.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Systemic Inflammatory Response Syndrome Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Indication Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

4.5. Porter’s Five Force Analysis

5. Market Outlook

5.1. Technological Advancements

5.2. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc.)

5.3. Regulatory Scenario, by Region/Country

5.4. Pipeline Analysis

5.5. Key product/brand Analysis

6. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by Indication

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Indication, 2017–2027

6.3.1. Meningitis

6.3.2. Urinary Tract Infection (UTI)

6.3.3. Pneumonia

6.3.4. Hemorrhage

6.3.5. Autoimmune Diseases

6.3.6. Others

6.4. Market Attractiveness, by Indication

7. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by End-user

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by End-user, 2017–2027

7.3.1. Hospital & Ambulatory Surgical Centers

7.3.2. Specialty Clinics

7.3.3. Others

7.4. Market Attractiveness, by End-user

8. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by Region

8.1. Key Findings

8.2. Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness, by Country/Region

9. North America Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast, by Indication, 2017–2027

9.2.1. Meningitis

9.2.2. Urinary Tract Infection (UTI)

9.2.3. Pneumonia

9.2.4. Hemorrhage

9.2.5. Autoimmune Diseases

9.2.6. Others

9.3. Market Value Forecast, by End-user, 2017–2027

9.3.1. Hospital & Ambulatory Surgical Centers

9.3.2. Specialty Clinics

9.3.3. Others

9.4. Market Value Forecast, by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis

9.5.1. By Indication

9.5.2. By End-user

9.5.3. By Country

10. Europe Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Indication, 2017–2027

10.2.1. Meningitis

10.2.2. Urinary Tract Infection (UTI)

10.2.3. Pneumonia

10.2.4. Hemorrhage

10.2.5. Autoimmune Diseases

10.2.6. Others

10.3. Market Value Forecast, by End-user, 2017–2027

10.3.1. Hospital & Ambulatory Surgical Centers

10.3.2. Specialty Clinics

10.3.3. Others

10.4. Market Value Forecast, by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Russia

10.4.7. Rest of Europe

10.5. Market Attractiveness Analysis

10.5.1. By Indication

10.5.2. By End-user

10.5.3. By Country/Sub-region

11. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Indication, 2017–2027

11.2.1. Meningitis

11.2.2. Urinary Tract Infection (UTI)

11.2.3. Pneumonia

11.2.4. Hemorrhage

11.2.5. Autoimmune Diseases

11.2.6. Others

11.3. Market Value Forecast, by End-user, 2017–2027

11.3.1. Hospital & Ambulatory Surgical Centers

11.3.2. Specialty Clinics

11.3.3. Others

11.4. Market Value Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Market Attractiveness Analysis

11.5.1. By Indication

11.5.2. By End-user

11.5.3. By Country/Sub-region

12. Latin America Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Indication, 2017–2027

12.2.1. Meningitis

12.2.2. Urinary Tract Infection (UTI)

12.2.3. Pneumonia

12.2.4. Hemorrhage

12.2.5. Autoimmune Diseases

12.2.6. Others

12.3. Market Value Forecast, by End-user, 2017–2027

12.3.1. Hospital & Ambulatory Surgical Centers

12.3.2. Specialty Clinics

12.3.3. Others

12.4. Market Value Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Market Attractiveness Analysis

12.5.1. By Indication

12.5.2. By End-user

12.5.3. By Country/Sub-region

13. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Indication, 2017–2027

13.2.1. Meningitis

13.2.2. Urinary Tract Infection (UTI)

13.2.3. Pneumonia

13.2.4. Hemorrhage

13.2.5. Autoimmune Diseases

13.2.6. Others

13.3. Market Value Forecast, by End-user, 2017–2027

13.3.1. Hospital & Ambulatory Surgical Centers

13.3.2. Specialty Clinics

13.3.3. Others

13.4. Market Value Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Israel

13.4.4. Rest of Middle East & Africa

13.5. Market Attractiveness Analysis

13.5.1. By Indication

13.5.2. By End-user

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Market Share Analysis, by Company, 2018

14.3. Company Profiles

14.3.1. CytoSorbents Corporation

14.3.1.1. Overview (HQ, Employee Strength, Business Segments)

14.3.1.2. Financials

14.3.1.3. Recent Developments

14.3.1.4. Strategy

14.3.2. RegeneRx Biopharmaceuticals, Inc.

14.3.2.1. Overview (HQ, Employee Strength, Business Segments)

14.3.2.2. Financials

14.3.2.3. Recent Developments

14.3.2.4. Strategy

14.3.3. Endacea, Inc.

14.3.3.1. Overview (HQ, Employee Strength, Business Segments)

14.3.3.2. Strategy

14.3.4. Adrenomed AG

14.3.4.1. Overview (HQ, Employee Strength, Business Segments)

14.3.4.2. Recent Developments

14.3.4.3. Strategy

14.3.5. GlaxoSmithKline plc

14.3.5.1. Overview (HQ, Employee Strength, Business Segments)

14.3.5.2. Financials

14.3.5.3. Recent Developments

14.3.5.4. Strategy

14.3.6. Asahi Kasei Corporation

14.3.6.1. Overview (HQ, Employee Strength, Business Segments)

14.3.6.2. Financials

14.3.6.3. Recent Developments

14.3.6.4. Strategy

14.3.7. Cardinal Health

14.3.7.1. Overview (HQ, Employee Strength, Business Segments)

14.3.7.2. Financials

14.3.7.3. Recent Developments

14.3.7.4. Strategy

14.3.8. Smith & Nephew plc

14.3.8.1. Overview (HQ, Employee Strength, Business Segments)

14.3.8.2. Financials

14.3.8.3. Recent Developments

14.3.8.4. Strategy

14.3.9. ConvaTec, Inc.

14.3.9.1. Overview (HQ, Employee Strength, Business Segments)

14.3.9.2. Financials

14.3.9.3. Recent Developments

14.3.9.4. Strategy

14.3.10. AstraZeneca

14.3.10.1. Overview (HQ, Employee Strength, Business Segments)

14.3.10.2. Financials

14.3.10.3. Recent Developments

14.3.10.4. Strategy

14.3.11. Orion Corporation

14.3.11.1. Overview (HQ, Employee Strength, Business Segments)

14.3.11.2. Financials

14.3.11.3. Recent Developments

14.3.11.4. Strategy

14.3.12. CHIESI Farmaceutici S.p.A.

14.3.12.1. Overview (HQ, Employee Strength, Business Segments)

14.3.12.2. Financials

14.3.12.3. Recent Developments

14.3.12.4. Strategy

14.3.13. Mylan N.V.

14.3.13.1. Overview (HQ, Employee Strength, Business Segments)

14.3.13.2. Financials

14.3.13.3. Recent Developments

14.3.13.4. Strategy

*Note: Financial details of companies that do not report this information in public domain might not have been captured